文献速递糖尿病肥胖与代谢综合征

达格列净对2型糖尿病患者能量代谢的影响:随机双盲交叉试验

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.
PubMed 文献 · Diabetes Care · 2021-04-15

该研究为5周随机双盲交叉试验,纳入26例2型糖尿病患者(可评估24例),探讨达格列净对24小时能量代谢和胰岛素敏感性的影响。结果显示达格列净不影响葡萄糖消失率,但增加空腹内源性葡萄糖生成,增强胰岛素对EGP和游离脂肪酸的抑制,降低呼吸交换率,导致24小时能量和脂肪负平衡。结论提示达格列净治疗引起类似热量限制的代谢调整,增加脂肪氧化,改善肝脏和脂肪组织胰岛素敏感性。

要点

  • 达格列净增加空腹内源性葡萄糖生成,但增强胰岛素对EGP的抑制。
  • 达格列净降低日间和夜间呼吸交换率,提示脂肪氧化增加。
  • 达格列净导致24小时能量和脂肪负平衡,类似热量限制效应。

核心结论

  • 达格列净治疗5周引起类似热量限制的代谢调整,增加脂肪氧化,改善肝脏和脂肪组织胰岛素敏感性,并改善24小时能量代谢。

研究设计与样本

  • 随机双盲交叉试验,26例2型糖尿病患者随机分配,洗脱期6-8周,可评估24例。
  • 采用间接测热法(全身室 calorimetry 和通风罩)测量24小时能量代谢和呼吸交换率,并进行两步正常血糖-高胰岛素钳夹。

主要发现

  • 葡萄糖消失率不受达格列净影响,而空腹内源性葡萄糖生成增加2.27 [1.39, 3.14] μmol/kg/min(P < 0.0001)。
  • 达格列净使胰岛素诱导的内源性葡萄糖生成抑制增强-1.71 [-2.75, -0.63] μmol/kg/min(P = 0.0036),血浆游离脂肪酸抑制增强-21.93% [-39.31, -4.54](P = 0.016)。
  • 24小时能量消耗无显著变化(-0.11 [-0.24, 0.03] MJ/day),但日间和夜间呼吸交换率降低,日间与夜间差值增加-0.010 [-0.017, -0.002](P = 0.016)。
  • 达格列净导致24小时能量和脂肪负平衡-20.51 [-27.90, -13.12] g/day。

临床怎么用

  • 达格列净可能通过增加尿糖排泄模拟热量限制,促进脂肪氧化,改善肝脏和脂肪组织胰岛素敏感性。
  • 临床使用达格列净时,可关注其对能量代谢和脂肪平衡的影响,尤其适用于需要改善胰岛素敏感性的2型糖尿病患者。

局限性

  • 样本量较小(可评估24例),研究周期较短(5周),可能限制结论的普遍性。
  • 研究未报告硬性临床结局,仅涉及代谢指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: There were 26 patients with type 2 diabetes randomized to a 5-week double-blind, crossover study with a 6- to 8-week washout. Indirect calorimetry was used to measure 24-h energy metabolism and the respiratory exchange ratio (RER), both by whole-room calorimetry and by ventilated hood during a two-step euglycemic-hyperinsulinemic clamp. Results are presented as the differences in least squares mean (95% CI) between treatments. RESULTS: Evaluable patients (n = 24) had a mean (SD) age of 64.2 (4.6) years, BMI of 28.1 (2.4) kg/m2, and HbA1c of 6.9% (0.7) (51.7 [6.8] mmol/mol). Rate of glucose disappearance was unaffected by dapagliflozin, whereas fasting endogenous glucose production (EGP) increased by dapagliflozin (+2.27 [1.39, 3.14] μmol/kg/min, P < 0.0001). Insulin-induced suppression of EGP (-1.71 [-2.75, -0.63] μmol/kg/min, P = 0.0036) and plasma free fatty acids (-21.93% [-39.31, -4.54], P = 0.016) was greater with dapagliflozin. Twenty-four-hour energy expenditure (-0.11 [-0.24, 0.03] MJ/day) remained unaffected by dapagliflozin, but dapagliflozin reduced the RER during daytime and nighttime, resulting in an increased day-to-nighttime difference in the RER (-0.010 [-0.017, -0.002], P = 0.016). Dapagliflozin treatment resulted in a negative 24-h energy and fat balance (-20.51 [-27.90, -13.12] g/day). CONCLUSIONS: Dapagliflozin treatment for 5 weeks resulted in major adjustments of metabolism mimicking caloric restriction, increased fat oxidation, improved hepatic and adipose insulin sensitivity, and improved 24-h energy metabolism.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Op den Kamp YJM, de Ligt M, Dautzenberg B, et al. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care. 2021. PMID: 33858855. doi:10.2337/dc20-2887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。